Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Health Care System
mi
from
Pembroke Pines, FL
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Health Care System
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital
mi
from
Atlanta, GA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Illinois at Chicago
mi
from
Chicago, IL
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland
mi
from
Baltimore, MD
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Med Ctr; Hem/Onc
mi
from
Boston, MA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Med Ctr; Hem/Onc
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Dana Farber Can Ins
mi
from
Boston, MA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Dana Farber Can Ins
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Washington Uni School of Medicine
mi
from
Saint Louis, MO
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Washington Uni School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center - Peak
mi
from
Las Vegas, NV
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center - Peak
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Lancaster General Hospital
mi
from
Lancaster, PA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Lancaster General Hospital
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center; Division of Hematology-Oncology
mi
from
Pittsburgh, PA
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center; Division of Hematology-Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Cancer Center, Tennessee Oncology
mi
from
Nashville, TN
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Cancer Center, Tennessee Oncology
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Kinghorn Cancer Centre; St Vincents Hospital
mi
from
Darlinghurst,
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Kinghorn Cancer Centre; St Vincents Hospital
mi
from
Darlinghurst,
Click here to add this to my saved trials
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
Bronx, NY
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Eribulin in Children With Cancer to Determine Safety
A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Jimmy Everest Center for Cancer and Blood Disorders in Children
mi
from
Oklahoma City, OK
Study of Eribulin in Children With Cancer to Determine Safety
A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Jimmy Everest Center for Cancer and Blood Disorders in Children
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Villejuif cedex,
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Villejuif cedex,
Click here to add this to my saved trials
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter Associated Bloodstream Infection: Impact on Length of Stay and Catheter Salvage
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Michigan
mi
from
Detroit, MI
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter Associated Bloodstream Infection: Impact on Length of Stay and Catheter Salvage
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  12/31/1969
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 12/31/1969
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Delaware/Christiana Care NCORP
mi
from
Newark, DE
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Delaware/Christiana Care NCORP
mi
from
Newark, DE
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Heartland NCORP
mi
from
Decatur, IL
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Heartland NCORP
mi
from
Decatur, IL
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Kansas City NCORP
mi
from
Prairie Village, KA
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Kansas City NCORP
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Wichita NCORP
mi
from
Wichita, KA
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Wichita NCORP
mi
from
Wichita, KA
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota NCORP
mi
from
Minneapolis, MN
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota NCORP
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Nevada NCORP
mi
from
Las Vegas, NV
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Nevada NCORP
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Southeast Clinical Oncology Research Consortium
mi
from
Winston-Salem, NC
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Southeast Clinical Oncology Research Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Columbus NCORP
mi
from
Columbus, OH
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Columbus NCORP
mi
from
Columbus, OH
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Pacific Cancer Research Consortium Ncorp
mi
from
Portland, OR
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Pacific Cancer Research Consortium Ncorp
mi
from
Portland, OR
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Institute NCORP
mi
from
Danville, PA
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Institute NCORP
mi
from
Danville, PA
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Greenville NCORP
mi
from
Greenville, SC
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Greenville NCORP
mi
from
Greenville, SC
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Aurora NCORP
mi
from
Milwaukee, WI
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Aurora NCORP
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Hawaii
mi
from
Honolulu, HI
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
Northwell Health
mi
from
Lake Success, NY
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
Northwell Health
mi
from
Lake Success, NY
Click here to add this to my saved trials
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
WiNCORP
mi
from
Marshfield, WI
Improving Communication in Older Cancer Patients and Their Caregivers
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
WiNCORP
mi
from
Marshfield, WI
Click here to add this to my saved trials